Vivos Therapeutics (VVOS) Cash from Operations Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 176.25 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.84 Bn | 99.62 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.32 Bn | 43.65 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.46 Bn | 26.18 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.46 Bn | 27.34 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | 0.50% |
| 10 | Vivos Therapeutics | 5.70 Mn | 3.59 Mn | 3.06 Mn | -19.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.24% |
| Dec 31, 2025 | -7.69% |
| Sep 30, 2025 | 10.42% |
| Jun 30, 2025 | 9.12% |
| Mar 31, 2025 | 14.51% |
| Dec 31, 2024 | 10.56% |
| Sep 30, 2024 | -1.13% |
| Jun 30, 2024 | 6.22% |
| Mar 31, 2024 | 13.30% |
| Dec 31, 2023 | 9.27% |
| Sep 30, 2023 | -60.72% |
| Jun 30, 2023 | -44.35% |
| Mar 31, 2023 | -100.83% |